anti-her2/her3 dendritic cell vaccine
Vaccineexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2020 (NCT04348747)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Receptor tyrosine-protein kinase erbB-3Immunity, active
ERBB3 immunity, active
- Receptor protein-tyrosine kinase erbB-2Immunity, active
ERBB2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04348747 | Phase 2 | Jun 1, 2020 | Department of Defense, State University of New York, Buffalo |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Department of Defense | Government | 1 | 0 | 1 | 2020 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1